Skip to main content
. Author manuscript; available in PMC: 2015 Mar 30.
Published in final edited form as: Neuroscience. 2013 Oct 22;256:322–333. doi: 10.1016/j.neuroscience.2013.10.027

Fig. 7.

Fig. 7

Transfection with miR-7-1 mimic followed by treatment with WAY or EST provided functional neuroprotection in VSC4.1 motoneurons. Treatment groups: untreated control (CTL), 200 nM CI for 24 h. 50 nM miR-7-1 for 12 h + 200 nM CI for 24 h, 50 nM miR-7-1 for 12 h + 200 nM CI for 24 h + 100 nM WAY for 24 h, 50 nM miR-7-1for 12 h + 200 nM CI for 24 h + 150 nM EST for 24 h. (A) Measurement of whole cell membrane potential. (B) Determination of JC-1 ratio (590 nm: 530 nm) at different time points (0 to 12 h). (C) Western blotting to show expression of COX-4, cytochrome c (Cyt c), Smac/Diablo, and β-actin. (D) Densitometric analysis to show percent changes in the mitochondrial and cytosolic cytochrome c (Cyt c) and cytosolic Smac/Diablo. Difference in values between CTL (the untreated group) and a treatment was considered significant at *p<0.05 or **p<0.01. Difference in values between the CI insulted cells and the miR-7-1 + CI or miR-7-1 + CI + ER agonist treated cells was considered significant at #p<0.05 or ##p <0.01.